Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 21, Issue 4, Pages -Publisher
SPRINGER
DOI: 10.1007/s11864-020-0711-9
Keywords
Peptide receptor radionuclide therapy (PRRT); Somatostatin analogues (SSAs); Somatostatin receptors (SSTRs); Toxicity; Myelodysplastic syndrome (MDS; Salvage therapy
Categories
Ask authors/readers for more resources
Opinion statement Neuroendocrine tumors (NETs) are a heterogenous group of neoplasms characterized by varied biological hallmarks and behavior, ranging from indolent to aggressive. For many decades, somatostatin analogues and few targeted therapies were available for NETs and these therapies had minimal response rates. However, there have been a number of recent treatment advances. Peptide receptor radionuclide therapy (PRRT) is a novel approach to treatment of NETs and has changed the landscape of treatment for NETs. It is a form of targeted therapy in which a radiolabeled somatostatin analogue delivers radiation specifically to tumor cells expressing the somatostatin receptor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available